- Home
- OVID vs OTLK Comparison
OVID vs OTLK Comparison
Compare OVID & OTLK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OVID
- OTLK
- Stock Information
- Founded
- OVID 2014
- OTLK 2010
- Country
- OVID United States
- OTLK United States
- Employees
- OVID N/A
- OTLK N/A
- Industry
- OVID Biotechnology: Pharmaceutical Preparations
- OTLK Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- OVID Health Care
- OTLK Health Care
- Exchange
- OVID Nasdaq
- OTLK Nasdaq
- Market Cap
- OVID 47.1M
- OTLK 56.3M
- IPO Year
- OVID 2017
- OTLK 2016
- Fundamental
- Price
- OVID $0.45
- OTLK $1.48
- Analyst Decision
- OVID Strong Buy
- OTLK Strong Buy
- Analyst Count
- OVID 6
- OTLK 5
- Target Price
- OVID $3.20
- OTLK $10.20
- AVG Volume (30 Days)
- OVID 312.2K
- OTLK 479.6K
- Earning Date
- OVID 03-11-2025
- OTLK 02-14-2025
- Dividend Yield
- OVID N/A
- OTLK N/A
- EPS Growth
- OVID N/A
- OTLK N/A
- EPS
- OVID N/A
- OTLK N/A
- Revenue
- OVID $566,000.00
- OTLK N/A
- Revenue This Year
- OVID N/A
- OTLK N/A
- Revenue Next Year
- OVID N/A
- OTLK $288.46
- P/E Ratio
- OVID N/A
- OTLK N/A
- Revenue Growth
- OVID 44.50
- OTLK N/A
- 52 Week Low
- OVID $0.46
- OTLK $0.87
- 52 Week High
- OVID $3.45
- OTLK $12.85
- Technical
- Relative Strength Index (RSI)
- OVID 30.65
- OTLK 40.05
- Support Level
- OVID $0.50
- OTLK $1.38
- Resistance Level
- OVID $0.58
- OTLK $1.51
- Average True Range (ATR)
- OVID 0.06
- OTLK 0.12
- MACD
- OVID 0.00
- OTLK 0.02
- Stochastic Oscillator
- OVID 13.30
- OTLK 38.86
About OVID Ovid Therapeutics Inc.
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential in-class mechanism of action.
About OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.